Cargando…

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study

BACKGROUND: Immune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs. METHODS: We described the case of a patient experiencing urinary incontinence who later...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yizhang, Lu, Wenchao, Tang, Borui, Zhao, Zhixia, An, Zhuoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510979/ https://www.ncbi.nlm.nih.gov/pubmed/36172143 http://dx.doi.org/10.3389/fonc.2022.954468

Ejemplares similares

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database
por: Hu, Fangyuan, et al.
Publicado: (2021)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
por: Jordan, B., et al.
Publicado: (2021)

Effects of Biofeedback in Preventing Urinary Incontinence and Erectile Dysfunction after Radical Prostatectomy
por: Perez, Fabiana S. B., et al.
Publicado: (2018)

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Xia, Shuang, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
por: Diaz, Laurine, et al.
Publicado: (2023)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer
por: Hasannejadasl, Hajar, et al.
Publicado: (2023)

Urinary incontinence after radical prostatectomy – experience of the last 100 cases
por: Sosnowski, Roman, et al.
Publicado: (2011)

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
por: Elias, Alexandra W., et al.
Publicado: (2017)

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review
por: Xiong, Ge, et al.
Publicado: (2023)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
por: Johns, Andrew C, et al.
Publicado: (2023)

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors
por: Du, Wei, et al.
Publicado: (2021)

Urinary Incontinence
por: Feneley, R.C.L., et al.
Publicado: (1982)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Evaluation of Possible Side Effects in the Treatment of Urinary Incontinence with Magnetic Stimulation
por: Pavčnik, Maja, et al.
Publicado: (2023)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects
por: Bresolin, Andrea, et al.
Publicado: (2020)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

A retrospective study of neuromuscular electrical stimulation for treating women with post-stroke incontinence
por: Shen, Shu-Xia, et al.
Publicado: (2018)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Pharmacovigilance of antimalarial treatment in Africa: is it possible?
por: Talisuna, Ambrose O, et al.
Publicado: (2006)

Urinary Incontinence: An Update
por: Zivkovic, Dragana, et al.
Publicado: (2019)

Clozapine and urinary incontinence
por: Osca Oliver, A., et al.
Publicado: (2022)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fvrk8hidrvh66idnippgslkib